Procter & Gamble Health Ltd Q1FY26 – “Vitamin Profits, Supplemented by Royalties: 36% ROE Served with 2% Dividend”
1. At a Glance
P&G Health (PGHL) – the Indian arm of the global FMCG–pharma monster – closed at ₹6,288 with a market cap of ₹10,433 Cr. FY25 sales were ₹1,273 Cr, with a juicy PAT of ₹301 Cr, giving it a P/E of ~35x. Dividend yield sits near 2%, and the company flaunts an ROE of 36% and ROCE of 48%. Compare this to the cement jokers we roasted last week – this one’s basically printing vitamins and dividends. In the last 6 months, the stock returned 22%, in 1 year 20%. Clearly, health is wealth… unless you’re paying 19x book value for it.
2. Introduction
P&G Health is like that one rich cousin who casually flexes – “I just do vitamins, bro” – and yet drives a BMW. Originally Merck Ltd, it was swallowed by P&G in 2018 as part of a $4.2B global deal. Since then, PGHL has become India’s biggest VMS (Vitamins, Minerals, Supplements) player.
Its products are less “pharma life-saving” and more “middle-class auntie swears by this” – Evion, Neurobion, Livogen, Nasivion, Seven Seas. Chances are your mom has at least one in her medicine cabinet.
This isn’t a mass generic play like Cipla or Dr Reddy’s. It’s premium OTC, high-margin, brand-led pharma. The Goa factory isn’t churning out injections anymore (outsourced since FY24) – instead, it makes sure you pop shiny supplements while sending royalties (₹24 Cr FY23) to Uncle P&G in the US.
Reader check: How do you feel about paying Wall Street royalties every time you swallow a Neurobion?
3. Business Model – WTF Do They Even Do?
The company is a pure-play branded pharma–consumer health business:
Revenue Split: 90% from India, 10% exports. Don’t expect global dominance – it’s very much a “Bharat vitamin business.”
Distribution: Transitioned in FY23 from carrying & forwarding agents to direct distributor-led model. Also ramping up omnichannel presence (online + offline pharmacies).
CSR/Marketing Disguised as Campaigns: Runs bus yatras for anemia awareness, and diabetes day campaigns – nice way to market without calling it marketing.
In short: PGHL is a Vitamin FMCG company masquerading as pharma – but in finance, that’s a compliment.
4. Financials Overview
Source table
Metric
Latest Qtr (Q1FY26)
YoY Qtr (Q1FY25)
Prev Qtr (Q4FY25)
YoY %
QoQ %
Revenue (₹ Cr)
339
284
311
19%
9%
EBITDA (₹ Cr)
90
48
81
88%
11%
PAT (₹ Cr)
66.2
25.6
61.0
158%
9%
EPS (₹)
39.9
15.4
36.9
159%
8%
Commentary: EPS annualised = ~₹160 → stock trading at forward PE ~39x. That’s pricey, but investors love margins + dividend combo.
